ROCKWELL MEDICAL, INC. 10-K — AI Bull & Bear Analysis

The 2025 10-K presents a company at a critical crossroads, balancing a necessary diversification of its customer base against significant financial headwinds. The transition from a DaVita-centric model to a broader market approach is the central theme of the filing. While the company has successfully maintained gross margins and expanded its regional footprint, the absolute decline in sales and the shift to a net loss of $5.3 million highlight the difficulty of this transition. Investors must weigh the potential of the new bicarbonate cartridge and new multi-year contracts against the looming risk of debt covenant breaches. The company's ability to survive and scale depends on whether the new customer acquisitions can offset the loss of DaVita's volume before the current cash runway is depleted. The overall impact of the filing is a shift in risk profile: Rockwell is no longer just betting on one customer, but it is now betting on its ability to out-compete industry giants in a fragmented market with limited capital.